Board of Directors

Andrew Sandham, (Chairman)
Aaron Davidson
Kenneth Galbraith
Jonathan R. Goodman
Richard Meadows
Deepa Pakianathan, PhD
Chau Q. Khuong

Leadership

Management Team
Board of Directors
Board Observers
Scientific Advisory Board

Aaron Davidson, Managing Director, H.I.G. Ventures

Aaron Davidson is a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G. in 2004, he was a Vice President with Ventures West with a focus on venture investing in life science companies. Mr. Davidson began his career with Lilly, where he spent a decade in various management roles in the United States and Canada including business development, strategic planning, market research and financial planning. After Lilly he spent a year as the Vice President of Corporate Business Development at SYN-X Pharma Inc. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals, Inc., HyperBranch Medical Technology, Inc., NeurAxon Inc., Novadaq Technologies Inc. and Tranzyme Pharma Inc. He served on the board of Salmedix Inc. prior to its acquisition by Cephalon, Inc. in June 2005 and the board of Oncogenex Pharmaceuticals Inc. prior to their public listing. Mr. Davidson earned his MBA from Harvard Business School and a Bachelor of Commerce degree from McGill University.